Clinical Trials
3 trialsNCT03907488 2026-06-01
Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT04404283 2026-04-20
ECHELON-3
Seagen Inc.
Phase 3 Active not recruiting
NCT02684292 2026-02-18
MK-3475-204
Merck Sharp & Dohme LLC
Phase 3 Completed